Taken together, PCSK9 inhibitors are recommended as additional or alternative therapy in patients with complete statin intolerance ASCVD and familial hypercholesterolemia (FH) with persistent hypercholesterolemia [138-140]. This evidence concerns the gene PCSK9 and atherosclerosis.